Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome
Background. The optimal duration of antithrombotic therapy (ATT) after patent foramen ovale (PFO) closure remains under debate. This study sought to compare the clinical outcome of patients receiving antithrombotic agents for a short (6 months) versus extended (>6 months) period after the procedu...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Interventional Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2022/6559447 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548641413267456 |
|---|---|
| author | Joelle Kefer Karlien Carbonez Sophie Pierard François-Pierre Mouthuy Andre Peeters Cedric Hermans Catherine Lambert Christophe DeMeester Thierry Sluysmans Agnes Pasquet |
| author_facet | Joelle Kefer Karlien Carbonez Sophie Pierard François-Pierre Mouthuy Andre Peeters Cedric Hermans Catherine Lambert Christophe DeMeester Thierry Sluysmans Agnes Pasquet |
| author_sort | Joelle Kefer |
| collection | DOAJ |
| description | Background. The optimal duration of antithrombotic therapy (ATT) after patent foramen ovale (PFO) closure remains under debate. This study sought to compare the clinical outcome of patients receiving antithrombotic agents for a short (6 months) versus extended (>6 months) period after the procedure. Methods. This was a retrospective cohort study using a propensity score matching analysis on 259 consecutive patients (131 males, 43 ± 10 years) undergoing PFO closure due to cryptogenic stroke, with complete follow-up (median duration of 10 [4–13] years). The outcome was compared between patients receiving short-term (Group short, N = 88) versus extended ATT (Group long, N = 171). Results. The PFO closure device was successfully implanted in all cases, with 3% of minor complications. After propensity score matching, there were no differences between Groups short and long in the rate of stroke (0.3 vs. 0.4% patient-year, p=1.00), bleeding (2 vs. 2% patient-year, p=0.17), and device thrombosis (0.3 vs. 0.1% patient-year; p=0.60). Univariate analysis showed that short-term ATT was not associated with an increased risk of recurrent stroke (HR: 1.271 [95% CI: 0.247–6.551], p=0.775) or prosthesis thrombus (HR: 0.50 [95% CI: 0.070–3.548], p=0.72). Kaplan–Meier analysis revealed similar overall survival in Group short and long (100 vs. 99 ± 1%, respectively; p=0.25). Conclusions. Short-term (6 months) ATT after PFO closure did not impair the clinical outcome, with a preserved low rate of recurrent stroke (0.3% patient-year) and device thrombosis (0.2% patient-year) at 10-year follow-up. |
| format | Article |
| id | doaj-art-dd35c86a5fe04d3ab9a4cbda14a562f4 |
| institution | Kabale University |
| issn | 1540-8183 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Interventional Cardiology |
| spelling | doaj-art-dd35c86a5fe04d3ab9a4cbda14a562f42025-02-03T06:13:33ZengWileyJournal of Interventional Cardiology1540-81832022-01-01202210.1155/2022/6559447Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term OutcomeJoelle Kefer0Karlien Carbonez1Sophie Pierard2François-Pierre Mouthuy3Andre Peeters4Cedric Hermans5Catherine Lambert6Christophe DeMeester7Thierry Sluysmans8Agnes Pasquet9Division of CardiologyDivision of Pediatric CardiologyDivision of CardiologyDivision of CardiologyDivision of NeurologyDivision of HematologyDivision of HematologyPôle de Recherche CardiovasculaireDivision of Pediatric CardiologyDivision of CardiologyBackground. The optimal duration of antithrombotic therapy (ATT) after patent foramen ovale (PFO) closure remains under debate. This study sought to compare the clinical outcome of patients receiving antithrombotic agents for a short (6 months) versus extended (>6 months) period after the procedure. Methods. This was a retrospective cohort study using a propensity score matching analysis on 259 consecutive patients (131 males, 43 ± 10 years) undergoing PFO closure due to cryptogenic stroke, with complete follow-up (median duration of 10 [4–13] years). The outcome was compared between patients receiving short-term (Group short, N = 88) versus extended ATT (Group long, N = 171). Results. The PFO closure device was successfully implanted in all cases, with 3% of minor complications. After propensity score matching, there were no differences between Groups short and long in the rate of stroke (0.3 vs. 0.4% patient-year, p=1.00), bleeding (2 vs. 2% patient-year, p=0.17), and device thrombosis (0.3 vs. 0.1% patient-year; p=0.60). Univariate analysis showed that short-term ATT was not associated with an increased risk of recurrent stroke (HR: 1.271 [95% CI: 0.247–6.551], p=0.775) or prosthesis thrombus (HR: 0.50 [95% CI: 0.070–3.548], p=0.72). Kaplan–Meier analysis revealed similar overall survival in Group short and long (100 vs. 99 ± 1%, respectively; p=0.25). Conclusions. Short-term (6 months) ATT after PFO closure did not impair the clinical outcome, with a preserved low rate of recurrent stroke (0.3% patient-year) and device thrombosis (0.2% patient-year) at 10-year follow-up.http://dx.doi.org/10.1155/2022/6559447 |
| spellingShingle | Joelle Kefer Karlien Carbonez Sophie Pierard François-Pierre Mouthuy Andre Peeters Cedric Hermans Catherine Lambert Christophe DeMeester Thierry Sluysmans Agnes Pasquet Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome Journal of Interventional Cardiology |
| title | Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome |
| title_full | Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome |
| title_fullStr | Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome |
| title_full_unstemmed | Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome |
| title_short | Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome |
| title_sort | antithrombotic therapy duration after patent foramen ovale closure for stroke prevention impact on long term outcome |
| url | http://dx.doi.org/10.1155/2022/6559447 |
| work_keys_str_mv | AT joellekefer antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT karliencarbonez antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT sophiepierard antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT francoispierremouthuy antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT andrepeeters antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT cedrichermans antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT catherinelambert antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT christophedemeester antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT thierrysluysmans antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome AT agnespasquet antithrombotictherapydurationafterpatentforamenovaleclosureforstrokepreventionimpactonlongtermoutcome |